The diagnosis and management of malignant phaeochromocytoma and paraganglioma

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 569-585

  Chrisoulidou, Alexandra ^a   Kaltsas, Gregory ^b,d   Ilias, Ioannis ^c   Grossman, Ashley B ^d  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c E Venizelou Hospital   (Greece)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE Y 90; ANGIOPEPTIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARABINOSIDE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; EVEROLIMUS; FLUORODOPA F 18; FLUOROURACIL; GELDANAMYCIN; IMATINIB; LOMUSTINE; METIROSINE; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE; TRACER; UNCLASSIFIED DRUG; VINCRISTINE;

ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CATECHOLAMINE RELEASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMOEMBOLIZATION; CHROMAFFIN CELL; CLINICAL FEATURE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE; GENE MUTATION; HUMAN; HYPOTHYROIDISM; INFECTION; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION; LIVER METASTASIS; LYMPHOCYTOPENIA; METASTASIS; MICROARRAY ANALYSIS; NEPHROTOXICITY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SUCCINATE DEHYDROGENASE SUBUNIT B GENE; THROMBOCYTOPENIA;

ADRENAL GLAND NEOPLASMS; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMAFFIN CELLS; COMBINED MODALITY THERAPY; ENDOCRINE SURGICAL PROCEDURES; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; RADIOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 35948976628     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0074     Document Type: Review

References (159)

1. Ahlman H 2006 Malignant phaeochromocytoma. State of the field with future projections. Annals of New York Academy of Sciences 1073 449-464.
2. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A et al. 2005 Genetic testing in phaeochromocytoma or functional paraganglioma. Journal of Clinical Oncology 23 8812-8818.
3. Amar L, Peyrard S, Rossignol P, Zinzindohoue F, Gimenez-Roqueplo AP & Plouin PF 2006 Changes in urinary total metanephrine excretion in recurrent and malignant phaeochromocytomas and secreting paragangliomas. Annals of New York Academy of Sciences 1073 383-391.
4. Anouar Y, Yon L, Guillemot J, Thouennon E, Barbier L, Gimenez-Roqueplo AP, Bertherat J, Lefebvre H, Klein M, Muresan M et al. 2006 Development of novel tools for the diagnosis and prognosis of phaeochromocytoma using peptide marker immunoassay and gene expression profiling approaches. Annals of New York Academy of Sciences 1073 533-540.
5. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R & Keiser HR 1988 Malignant phaeochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Annals of Internal Medicine 109 267-273.
6. 131I]metaiodobenzylguanidine treatment of a malignant phaeochromocytoma. Journal of Nuclear Biology and Medicine 35 313-314.
7. Bausch B, Koschker AC, Fassnacht M, Stoevesandt J, Hoffmann MM, Eng C, Allolio B & Neumann HP 2006 Comprehensive mutation scanning of NF1 in apparently sporadic cases of pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 91 3478-3481.
8. Baysal BE 2006 A phenotypic perspective on mammalian oxygen sensor candidates. Annals of New York Academy of Sciences 1073 221-233.
9. Benn DE, Richardson AL, Marsh DJ & Robinson BG 2006 Genetic testing in phaeochromocytoma and paraganglioma-associated syndromes. Annals of New York Academy of Sciences 1073 104-111.
10. Bestagno M, Pizzocaro C, Maira G, Terzi A, Panarotto MB & Guerra P 1991 Results of [131]metaiodobenzylguanidine treatment in malignant phaeochromocytoma. Journal of Nuclear Biology and Medicine 35 277-279.
11. Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeny AT, Mueller PR, Hann PF & Boland G 2004 Phaeochromocytoma: an imaging chameleon. Radiographics 24 S87-S99.
12. Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang-Vu C, Roessner A & Lehnert H 2003 Expresssion profile of the telomeric complex discriminates between benign and malignant phaeochromocytoma. Journal of Clinical Endocrinology and Metabolism 88 4280-4286.
13. 131I-metaiodobenzylguanidine. Nuclear Medicine Communications 14 856-861.
14. Brauckhoff M, Gimm O & Dralle H 2004 Preoperative and surgical therapy in sporadic and familial phaeochromocytoma. Lehnert H (eds): Phaeochromocytoma, Pathophysiology and clinical management. Frontiers of Hormone Research 31 121-144.
15. Bravo EL 1994 Evolving concepts in the pathophysiology, diagnosis and treatment of phaeochromocytoma. Endocrine Reviews 15 356-368.
16. Bravo EL & Tagle R 2003 Phaeochromocytoma: state of the art and future prospects. Endocrine Reviews 24 539-553.
17. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K 2006a High frequency of SDHB gerline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 91 4505-4509.
18. Brouwers FM, Elkahloun AG, Munson PJ, Eisenhofer G, Barb J, Lineham WM, Lenders JW, De Krijger R, Manelli M, Udelsman R et al. 2006b Gene Expression Profiling of Benign and Malignant Phaeochromocytoma. Annals of New York Academy of Sciences 1073 541-556.
19. Brown HM, Komorowski RA, Wilson SD, Demeure MJ & Zhu Y 1999 Predicting metastasis of phaeochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation. Cancer 86 1583-1589.
20. Buhl T, Mortensen J & Kjaer A 2002 I-123 MIBG imaging and intraoperative localization of metastatic phaeochromocytoma: a case report. Clinical Nuclear Medicine 27 183-185.
21. 131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumors depends on initial response. Nuclear Medicine Communications 26 969-976.
22. 131I-MIBG scanning. Clinical Nuclear Medicine 21 960-963.
23. 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumors. Experience of the National Cancer institute of Milan. Quarterly Journal of Nuclear Medicine 44 77-87.
24. 131I]metaiodobenzyluanidine therapy administered in metastatic malignant phaeochromocytoma. Journal of Nuclear Biology and Medicine 35 300-304.
25. Coutant R, Pein F, Adamsbaum C, Oberlin O, Dubousset J, Guinebretiere JM, Teinturier C & Bougneres PF 1999 Prognosis of children with malignant phaeochromocytoma. Hormone Research 52 145-149.
26. Dahia PL, Aguiar RC, Tsanaclis AM, Bendit I, Bydlowski SP, Abelin NM & Toledo SP 1995 Molecular and immunohistochemical analysis of p53 in phaeochromocytoma. British Journal of Cancer 72 1211-1213.
27. Dahia PLM, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS et al. 2005 A HIF1a regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 1 72-80.
28. 131I-MIBG scintigraphy for diagnosis and follow-up of pheocrhomocytoma. Journal of Nuclear Medicine 42 993-997.
29. Dubois LA & Gray DK 2005 Dopamine-secreting phaeochromocytomas:in search of a syndrome. World Journal of Surgery 29 909-913.
30. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Manelli M, Goldstein DS, Linehan WM, Lenders JW et al. 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Journal of Clinical Endocrinology and Metabolism 86 1999-2008.
31. Eisenhofer G, Goldstein DS, Kopin IJ & Crout JR 2003 Phaeochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocrine Pathology 14 193-211.
32. Eisenhofer G, Bornstein S, Brouwers F, Cheung NV, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H et al. 2004a Malignant phaeochromocytoma:current status and initiatives for future progress. Endocrine-Related Cancer 11 423-436.
33. Eisenhofer G, Lenders JWM & Pacak K 2004b Biochemical diagnosis of pheochromocytoma. Lehnert H (eds): Phaeochromocytoma, Pathophysiology and clinical management. Frontiers of Hormone Research 31 76-106.
34. Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Browers FM, Lai EW, Adams KT & Pacak K 2005 Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. Journal of Clinical Endocrinology and Metabolism 90 2068-2075.
35. Elder EE, Elder G & Larsson C 2005 Phaeochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. Journal of Surgical Oncology 89 193-201.
36. Eriksson B & Oberg K 1999 Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: a future outlook. Annals of Oncology 10 S31-S38.
37. 131I]-metaiodobenzylguanidine in the treatment of neural crest tumors', Rome. Abstract 42.
38. Favier J, Plouin PF, Corvol P & Gase JM 2002 Angiogenesis and vascular architecture in phaeochromocytomas: distinctive traits in malignant tumors. American Journal of Pathology 161 1235-1246.
39. Fernandez-Cruz L, Saenz A, Taura P, Sabater L, Astudillo E & Fontanals J 1998 Helium and carbon dioxide pheumoperitoneum in patients with phaeochromocytoma undergoing laparoscopic adrenalectomy. World Journal of Surgery 22 1250-1255.
40. Fisher M 1991 Therapy of pheochromocytoma with [131] metaiodobenzylguanidine. Journal of Nuclear Biology and Medicine 35 292-294.
41. 131I-MIBG). Annals of New York Academy of Sciences 1073 465-490.
42. Forssell-Aronsson E, Bernhardt P, Wangberg B, Kolby L, Nilsson O & Ahlmann H 2006 Aspects on radionuclide therapy in malignant phaeochromocytomas. Annals of New York Academy of Sciences 1073 498-504.
43. Francis IR & Korobkin M 1996 Phaeochromocytoma. Radiologic Clinics of North America 34 1101-1112.
44. 131I- metaiodobenzylguanidine. Cancer 97 1332-1338.
45. Gimenez-Roqueplo AP, Lehnert H, Manelli M, Neumann H, Opocher G, Maher ER, Plouin PF & On behalf of the European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group 2006 Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology 65 699-705.
46. 123I-MIBG scan. Quarterly Journal of Nuclear Medicine and Molecular Imaging 50 344-347.
47. Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL et al. 1999 Clinical experience over 48 years with phaeochromocytoma. Annals of Surgery 229 755-766.
48. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A et al. 2006 The Israel Glivec in Solid Tumors Study Group, The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer 13 535-540.
49. Grossman AB & Kaltsas GA 2002 Adrenal medulla and pathology. In Comprehensive Clinical Endocrinology,edn 3, pp 223-237. Eds M Besser & MO Thorner. Philadelphia: Elsevier Science.
50. Grossman A, Pacak K, Sawka A, Lenders JW, Harlander D, Peaston RT, Reznek R, Sisson J & Eisenhofer G 2006 Biochemical diagnosis and localization of phaeochromocytoma. Can we reach a consensus? Annals of New York Academy of Sciences 1073 332-347.
51. Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, Rossetti O, Marocchi A, Bertuzzi M & Loli P 2006 The role of chromogranin A in the management of patients with phaechromocytoma. Clinical Endocrinology 65 287-293.
52. Guignat L, Bidart JM, Nocera M, Comoy E, Schlumberger M & Baudin E 2001 Chromogranin A and the alpha-subunit of glucoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. British Journal of Cancer 84 808-812.
53. Guillemot J, Barbier L, Thouennon E, Vallet-Erdtmann V, Montero-Hadjadje M, Lefebvre H, Klein M, Muresan M, Plouin PF, Seidah N et al. 2006 Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant phaeochromocytomas. Annals of New York Academy of Sciences 1073 527-532.
54. Gullu S, Gursoy A, Erdogan MF, Dizbaysak S, Erdogan G & Kamel N 2005 Multiple endocrine neoplasia type 2A/localized cutaneous lichen amyloidosis associated with malignant phaeochromocytoma and ganglioneuroma. Journal of Endocrinological Investigation 28 734-737.
55. Van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH & Boomsma F 2002 The value of plasma markers for the clinical behavior of phaeochromocytomas. European. Journal of Endocrinology 147 85-94.
56. Hartley A, Spooner D & Brunt AM 2001 Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clinical Oncology 13 361-366.
57. Helman LJ, Cohen PS, Avenbuch SD, Cooper MJ, Keiser HR & Israel MA 1989 Neuropeptide Y expression distiguishes malignant from benign phaeochromocytomas. Journal of Clinical Oncology 7 1720-1725.
58. De Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ & Krenning EP 2005 Neuroendocrine tumors and somatostatin: imaging techniques. Journal of Endocrinological Investigation 28 132-136.
59. 131I]-metaiodobenzylguanidine therapy of malignant phaeochromocytoma: interference of medication. Journal of Nuclear Biology and Medicine 35 305-307.
60. 18F DOPA whole-body PET-initial results. Radiology 222 507-512.
61. Ilias I & Pacak K 2005 Diagnosis and management of tumors of the adrenal medulla. Hormone and Metabolic Research 37 717-721.
62. Ilias I & Pacak K 2004 Current approaches and recommended algorithm for the diagnostic localization of phaeochromocytoma. Journal of Clinical Endocrinology and Metabolism 89 479-491.
63. 131I]-Metaiodobenzylguanidine scintigraphy in the localization of metastatic phaeochromocytoma. Journal of Clinical Endocrinology and Metabolism 88 4083-4087.
64. Ilias I, Sahdev A, Reznek RH, Grossman AB & Pacak K 2007 The optimal imaging of adrenal tumours:a comparison of different methods. Endocrine-Related Cancer 14 587-599.
65. Iwabuchi M, Oki Y & Nakamura H 1999 Palliative chemotherapy for malignant phaeochromocytoma: symptomatic palliation of two cases. Internal Medicine 38 433-435.
66. Jenkins SA, Kynaston HG, Davies ND, Baxter JN & Nott DM 2001 Somatostatin analogues in oncology: a look to the future. Chemotherapy 47 162-196.
67. John H, Ziegler WH, Hauri D & Jaeger P 1999 Phaeochromocytomas: can malignant potential be predicted? Urology 53 679-683.
68. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S & Krenning EP 2002 Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Seminars in Nuclear Medicine 32 133-140.
69. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R et al. 2001a Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Journal of Endocrinology and Metabolism 86 895-902.
70. Kaltsas G, Mukherjee JJ, Plowman PN & Grossman AB 2001b The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumors. Clinical Endocrinology 55 575-587.
71. Kaltsas G, Mukherjee JJ & Grossman AB 2001c The value of radiolabeled MIBG and octreotide in the diagnosis and treatment of neuroendocrine tumors. Annals of Oncology 12 S47-S50.
72. 131I-Meta-Iodobenzylguanidine (MIBG). Endocrinologist 13 1-13.
73. Kaltsas GA, Besser GM & Grossman AM 2004a The diagnosis and management of advanced neuroendocrine tumors. Endocrine Reviews 25 458-511.
74. Kaltsas GA, Papadogias D & Grossman A 2004b In Phaeochromocytoma. Pathophysiology and Clinical Management, Frontiers of Hormone Research, vol 31, pp 61-75. Ed H Lehnert, Basel: Karger.
75. Kaltsas GA, Papadogias D, Makras P & Grossman AB 2005 Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocrine-Related Cancer 12 683-699.
76. Kasperlik-Zalucka AA, Roslonowska E, Slowinska-Srzednicka J, Otto M, Cichocki A, Cwikla J, Slapa R & Eisenhofer G 2006 1111 patients with adrenal incidentalomas observed at a single endocrinological center:incidence of chromaffin tumors. Annals of New York Academy of Sciences 1073 38-46.
77. Kebebew E & Duh Q-Y 1998 Benign and malignant phaeochromocytoma. Surgical Oncology Clinics of North America 7 765-789.
78. Khorram-Manesh A, Ahlman H, Jansson S & Nilsson O 2002 N-cadherin expression in adrenal tumors:upregulation in malignant phaeochromocytoma and downregulation in adrenocortical carcinoma. Endocrine Pathology 13 99-110.
79. Koch CA, Vortmeyer AO, Huang SC, Alesci S, Zhuang Z & Pacak K 2001 Genetic aspects of pheochromocytoma. Endocrine Regulations 35 43-52.
80. Kolby L, Bernhardt P, Johanson V, Wangberg B, Muth A, Jansson S, Forsell-Aronson E & Nilsson O 2006 Ahlman, can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant phaeochromocytomas? Annals of New York Academy of Sciences 1073 491-497.
81. Kopf D, Goretzki P & Lehnert H 2001 Clinical management of malignant adrenal tumors. Journal of Cancer Research and Clinical Oncology 127 143-155.
82. Korpershoek E, Van Nederveen FH, Dannenberg H, Petri BJ, Komminoth P, Perren A, Lenders JW, Verhofstad AA, De Herder WW, De Krijger RR et al. 2006 Genetic analyses of apparently sporadic phaeochromocytomas. The Rotterdam experience. Annals of New York Academy of Sciences 1073 138-148.
83. 131I]metaiodobenzylguanidine: a French multicentric study. Journal of Nuclear Biology and Medicine 35 284-287.
84. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A & Fuchs CS 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 24 401-406.
85. 131I-metaiodobenzylguanidine therapy in two patients with malignant phaeochromocytoma. Journal of Clinical Endocrinology and Metabolism 90 5888-5895.
86. Lawrence JK, Maher ER, Sheaves R & Grossman AB 2004 Familial paraganglioma: a novel presentation of a case and response to therapy with radiolabeled MIBG. Hormones 3 127-131.
87. Lehnert H, Mundschenk J & Hann K 2004 Malignant phaeochromocytoma In Lehnert H (eds) Phaeochromocytoma. Pathophysiology and clinical management. Frontiers of Hormone Reasearch 155-162.
88. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Reiser HR, Goldstein DS & Eisenhofer G 2002 Biochemical diagnosis of phaeochromocytoma:which test is best? JAMA 287 1427-1434.
89. Lewington VJ, Zivanovic MA, Tristam M, Mc Ewan AJ & Ackery DM 1991 Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. Journal of Nuclear Biology and Medicine 35 280-283.
90. 131I-MIBG): A comprehensive review of 116 reported patients. Journal of Endocrinological Investigation 20 648-658.
91. 131I]metaiodobenzylguanidine therapy in 20 patients with malignant phaeochromocytoma. Journal of Nuclear Biology and Medicine 35 288-291.
92. 18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic phaeochromocytoma sites. Nuclear Medicine Communications 27 31-36.
93. Mannelli M, Simi L, Gagliano MS, Opocher G, Ercolino T, Becherini L & Parenti G 2007 Genetics and biology of pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes 115 160-165.
94. Maurea S, Cuocolo A, Reynolds JC, Neumann RD & Salvatore M 1996 Diagnostic imaging in patients with paragangliomas, computed tomography, magnetic resonance and MIBG scintigraphy comparison. Quarterly Journal of Nuclear Medicine 40 365-371.
95. McNeil AR, Blok BH, Koelmeyer TD, Burke MP & Hilton JM 2000 Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Australian and New Zealand Journal of Medicine 30 648-652.
96. Moreno AM, Castilla-Guerra L, Martinez-Torres MC, Torres-Olivera F, Fernandez E & Galera-Davidson H 1999 Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides 33 159-163.
97. Mornex R, Badet C & Peyrin L 1992 Malignant phaeochromocytoma: a series of 14 cases observed between 1966 and 1990. Journal of Endocrinological Investigation 15 643-649.
98. 131I -MIBG). Clinical Endocrinology 55 47-60.
99. 131I-MIBG. Annals of Nuclear Medicine 8 259-268.
100. Nakane M, Takahashi S, Sekine I, Fukui I, Koizumi M, Kage K, Ito Y, Aiba K, Horikoshi N, Hatake K et al. 2003 Successful treatment of malignant phaeochromocytoma with combination chemotherapy containing anthracycline. Annals of Oncology 14 1449-1451.
101. Nativ O, Grant CS, Sheps SG, O'Fallon JR, Farrow GM, van Heerden JA & Lieber MM 1992 The clinical significance of nuclear DNA ploidy pattern in 184 patients with phaeochromocytoma. Cancer 69 2683-2687.
102. Neumann HPH, Hoegerle S, Manz T, Brenner K & Iliopoulos O 2002a How many pathways to phaeochromocytomas. Seminars in Nephrology 22 88-99.
103. Neumann HPH, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K et al. 2002b Germ-line mutations in nonsyndromic phaeochromocytoma. New England Journal of Medicine 19 1459-1465.
104. Nguyen-Martin MA & Hammer GD 2006 Phaeochromocytoma: an update on Risk Groups. Diagnosis, and Management. Hospital Physician 42 17-24.
105. O'Connor DT & Bernstein KN 1984 Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with phaeochromocytoma. New England Journal of Medicine 311 764-770.
106. Oishi S & Sato T 1988 Elevated neuron specific enolase in patients with malignant phaeochromocytoma. Cancer 61 1167-1170.
107. O'Riordain DS, Young WF Jr, Grant CS, Carney JA & van Heerden JA 1996 Clinical spectrum and outcome of functional extraadrenal paraganglioma. World Journal of Surgery 20 916-922.
108. Pacak K, Ghrousos GP, Koch CA, Lendes JW & Eisenhofer G, 2001a Phaeochromocytoma:Progress in diagnosis, therapy and genetics. In Adrenal Disorders, pp 479-523. Eds A Margioris & GP Ghrousos Totowa: Humana Press.
109. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R & Eisenhofer G 2001b A 'pheo' lurks: novel approaches for locating occult phaeochromocytoma. Journal of Clinical Endocrinology and Metabolism 86 3641-3646.
110. Pacak K, Linehan WM, Eisenhofer G, Walther MM & Goldstein DS 2001c Recent advances in genetics, diagnosis, localization, and treatment of phaeochromocytoma. Annals of Internal Medicine 134 315-329.
111. Pacak K, Eisenhofer G & Ilias I 2004 Diagnostic imaging of phaeochromocytoma. Frontiers of Hormone Research Basel Karger, 31 107-120.
112. Pacak K, Eisenhofer G, Ahlman H, Bornstein S, Gimenez-Roqueplo A-P, Grossman AB, Kimura N, Mannelli M, McNicol A-M & Tischler AS 2007 Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice. Endocrinology and Metabolism 3 92-102.
113. Park JW, Yeh MW, Wong MG, Lobo M, Hyun WC, Duh QY & Clark OH 2003 The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, downregulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. Journal of Clinical Endocrinology and Metabolism 88 3346-3353.
114. Portela-Gomes GM, Stridsberg M, Grimelius L, Falkmer UG & Falkmer S 2004 Expression of chromogranins A, B and C (secretogranin II) in human adrenal medulla and in benign and malignant phaeochromocytomas. An immunohistochemical study with region-specific antibodies. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 112 663-673.
115. Portel-Gomes GM, Grimelius L, Johansson H, Wilander E & Stridsberg M 2001 Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. American Journal of Pathology 25 1261-1267.
116. Proye C, Fossati P, Fontaine P, Lefebvre J, Decoulx M, Wemeau JL, Dewailly D, Rwamasirabo E & Cecat P 1986 Dopamine secreting phaeochromocytoma: An unrecognized entity?, Classification of phaeochromocytoma according to their type of secretion Surgery 100 1154-1161.
117. Pujol P, Bringer J, Faurous P & Jaffiol C 1995 Metastatic phaechromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy. European Journal of Nuclear Medicine 22 382-384.
118. Quissel B, Mohammad A, Bauer JH & Hakami N 1979 Malignant phaeochromocytoma in childhood: report of a case with familial neurofibromatosis. Medical and Pediatric Oncology 7 327-333.
119. Rao F, Keiser HR & O'Connor DT 2000 Malignant phaeochromocytoma, Chromaffin granule transmitters and response to treatment. Hypertension 36 1045-1052.
120. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant phaeochromocytoma. Cancer 98 239-248.
121. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, Tyler DG & Olson JA 2003 Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant phaeochromocytoma and paraganglioma. Surgery 134 956-963.
122. Sahdev A & Reznek RH 2004 Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends in Endocrinology and Metabolism 15 271-276.
123. 131I-metaiodobenzylguanidine for malignant phaeochromocytoma. Annals of Nuclear Medicine 8 133-137.
124. Salmenkivi K, Arola J, Voutilainen R, Ilvesmaki V, Haglund C, Kahri AI, Heikkila P & Liu J 2001a Inhibin/activin βB-subunit expression in phaeochromocytomas favors benign diagnosis. Journal of Clinical Endocrinology and Metabolism 86 2231-2235.
125. Salmenkivi K, Haglund C, Ristimati A, Arola J & Heikkila P 2001b Increased expression of cyclooxygenase-2 in malignant phaeochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 5615-5619.
126. Salmenkivi K, Heikkila P, Haglund C, Louhimo J & Arola J 2003 Lack of histologically suspicious features, proliferative activity and p53 expression suggests benign diagnosis in phaeochromocytomas. Histopathology 43 62-71.
127. Sausville EA, Tomaszewski JE & Ivy P 2003 Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Current Cancer Drug Targets 3 377-383.
128. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Giuliani PP, Aubert B & Travagli JP 1992 Malignant phaeochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. Journal of Endocrinological Investigation 15 631-642.
129. Scholz T, Eisenhofer G, Pacak K, Dralle H & Lehnert H 2007 Current treatment of malignant pheohromocytoma. Journal of Clinical Endocrinology and Metabolism 92 1217-1225.
130. 131I] metaiodobenzylguanidinine therapy administered to three patients with malignant phaeochromocytoma. Journal of Nuclear Biology and Medicine 35 305-307.
131. Scott HW Jr & Halter SA 1984 Oncologic aspects of phaeochromocytoma: the importance of follow-up. Surgery 96 1061-1066.
132. 131I] metaiodobenzylguanidine in the treatment of neural crest tumors. Journal of Nuclear Biology and Medicine 35 357-363.
133. Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E, Gross MD, Carey JE, Zasadny KR & Beierwaltes WH 1991 Radiopharmaceutical therapy of malignant phaeochromocytoma: results from ten years of experience. Journal of Nuclear Biology and Medicine 35 269-276.
134. Shapiro B, Sisson JC, Shulkin BL, Gross MD & Zempel S 1995 The current status of radioiodinated metaiodobenzylguanidinine therapy of neuro-endocrine tumors. Quarterly Journal of Nuclear Medicine 39 55-57.
135. Shapiro B, Gross MD & Shulkin B 2001 Radioisotope diagnosis and therapy of malignant phaeochromocytoma. Trends in Endocrinology and Metabolism 12 469-475.
136. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B & Kuhl DE 1992 PET scanning with hydroxyephedrine: an approach to the localization of phaeochromocytoma. Journal of Nuclear Medicine 33 1125-1131.
137. Shulkin BL, Wieland DM, Shapiro B & Sisson JC 1995 PET adrenaline studies in phaeochromocytoma. Journal of Nuclear Medicine 36 229P.
138. Shulkin BL, Thompson NW, Shapiro B, Francis IR & Sisson JC 1999 Phaeochromocytomas: Imaging ith 2-deoxy-D-glucose PET. Radiology 212 35-41.
139. Shulkin B, Ilias I, Sisson J & Pacak K 2006 Current trends in functional imaging of phaeochromocytomas and paragangliomas. Annals of New York Academy of Sciences 1073 374-382.
140. Sigmund HE, Weitzman S, Thorner P, Seagram CG & Filler RM 1994 Pediatric malignant phaeochromocytoma. Journal of Pediatric Surgery 29 1197-1201.
141. Sisson J, Shapiro B, Beierwaltes W, Glowniak JV, Nakajo M, Mangner TJ, Carey JE, Swanson DP, Copp JE, Satterlee WG et al. 1984 Radiopharmaceutical treatment of malignant phaeochromocytoma. Journal of Nuclear Medicine 24 197-206.
142. Sisson JC, Shapiro B, Hutchinson RJ, Carey JE, Zasadny KR, Zemple SA & Normolle DP 1994 Predictor of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. European Journal of Nuclear Medicine 21 46-52.
143. 131I- metaiodobenzylguanidinine and chemotherapy. American Journal of Clinical Oncology 22 356-370.
144. Stoppa-Lyonnet D & Lenoir G 2005 Prédispositions génetiques aux cancers: actualités et perspectives en 2005. Medical Science 21 962-968.
145. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW & Nelkin BD 2006 Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 79-84.
146. Tada K, Okuda Y & Yamashita K 1998 Three cases of malignant phaeochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alphamethyl-p-tyrosine to control hypercatecholaminemia. Hormone Research 49 295-297.
147. Takahashi K, Ashizawa N, Minami T, Suzuki S, Sakamoto I, Hayashi K, Tomiyasu S, Sumikawa K, Kitamura K, Eto T et al. 1999 Malignant phaeochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Internal Medicine 38 349-354.
148. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B & Parmentier C 1995 Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant phaeochromocytoma. Journal of Nuclear Medicine 36 1-6.
149. Teno S, Tanabe A, Nomura K & Demura H 1996 Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic phaeochromocytoma. Endocrine Journal 43 511-516.
150. 131I- metaiodobenzylguanidine. Acta Oncologica 27 296-297.
151. Tonkin AL, Frewin DB, Russell WJ & Jonsson JR 1994 Phaeochromocytoma: intraoperative changes in blood pressure and plasma catecholamines. Clinical Autonomic Research 4 167-173.
152. 131I]-metaiodobenzylguanidine treatment of malignant phaeochromocytoma: experience of the Rome group. Journal of Nuclear Biology and Medicine 35 295-299.
153. 131I-MIBG therapy of neural crest tumours. Anticancer Research 17 1823-1832.
154. 131I]-metaiodobenzylguanidine in treatment of malignant phaeochromocytomas. Lancet 2 107.
155. Vezzosi D, Bouisson M, Escourrou G, Laurell H, Selves J, Seguin P, Pradayol L, Caron P & Buscail L 2006 Clinical utility of telomerase for the diagnosis of malignant well-differentiated endocrine tumours. Clinical Endocrinology 64 63-67.
156. Wiseman GA & Kvols LK 1995 Therapy of neuroendocine tumors with radiolabelled MIBG and somatostatin analogues. Seminars in Nuclear Medicine 115 272-278.
157. Wu LT, Dicpinigaitis P, Bruckner H, Manger W & Averbuch S 1994 Hypertensive crises induced by treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Medical and Pediatric Oncology 22 389-392.
158. Young AL, Baysal BE, Deb A & Young W Jr 2002 Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation of the succinate dehydrogenase B gene. Journal of Endocrinology and Metabolism 87 4101-4105.
159. Zarnegar R, Kebebew E, Duh QY & Clark OH 2006 Malignant pheochromocytoma. Surgical Oncology Clinics of North America 15 55-571.